A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged 50-80 years.
Phase 1
- Conditions
- The vaccine is designed to provide protection against circulating influenza and is being used in the UK influnza immunisation programme 2006-7MedDRA version: 8.1 Level: LLT Classification code 10022000 Term: Influenza
- Registration Number
- EUCTR2006-006563-23-GB
- Lead Sponsor
- Health Protection Agency
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•No contraindications to vaccination as specified in the Green Book” – Immunisation Against Infectious Disease, HMSO.
•Written informed consent obtained
•Subject aged no less than 50 years 0 days and no older than 79 years and 364 days at enrolment
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
none
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method